Increasing Medical Marijuana and Cannabidiol Research
- Executive Order Number
- 14370
- President
- Donald Trump
- Signed
- December 18, 2025
- Published
- December 23, 2025
- Source
- Federal Register
- Original Document
- https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23846.pdf
AI-Generated Summary
Summary of Executive Order on Medical Marijuana and Cannabidiol Products
Purpose
The executive order aims to recognize the medical uses of marijuana, supported by FDA and HHS findings for conditions like pain, anorexia, and chemotherapy-induced nausea/vomiting. It seeks to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), enhance research on medical marijuana and hemp-derived cannabinoid products (e.g., CBD), and improve patient/doctor guidance on safety, efficacy, and risks, particularly for vulnerable populations like seniors and adolescents.
Key Actions or Directives
- Expedite Rescheduling: The Attorney General must complete the rulemaking process to move marijuana to Schedule III of the CSA as quickly as possible, in line with federal law (21 U.S.C. 811).
- Legislative and Regulatory Efforts for Hemp-Derived Products:
- The Assistant to the President for Legislative, Political, and Public Affairs shall collaborate with Congress to update the statutory definition of final hemp-derived cannabinoid products, enabling access to full-spectrum CBD while restricting risky products.
- Develop a regulatory framework, including guidance on THC limits per serving/container and CBD:THC ratios.
- Research Enhancements: The Secretary of HHS, FDA Commissioner, CMS Administrator, and NIH Director shall create research methods/models using real-world evidence to assess health outcomes, long-term effects, and standards of care for medical marijuana and legal CBD products.
- Implementation Notes: Actions are subject to applicable law, appropriations, and do not alter existing agency authorities or create enforceable rights.
Significant Changes to Policy or Law
- Policy Shift: Moves from decades of federal neglect of marijuana's medical uses (Schedule I status) toward acceptance of its medical applications (aligning with Schedule III criteria: accepted medical use, moderate/low abuse potential).
- No Direct Legal Changes: Does not amend statutes but accelerates ongoing DEA proposed rulemaking (initiated May 2024) and urges congressional updates to hemp definitions (e.g., under 7 U.S.C. 1639o and Public Law 119-37).
- Research Focus: Emphasizes real-world evidence to bridge gaps in FDA approval, product labeling accuracy, and guidance on drug interactions.
Potential Impacts
- Government Agencies: Increased workload for DOJ/DEA (rulemaking), HHS/FDA/NIH/CMS (research/models), with expedited timelines; costs borne by HHS.
- Citizens: Improved access to medical marijuana/CBD for ~6 million patients treating 15+ conditions; potential reductions in opioid use (e.g., among veterans); better safety info reducing risks like drug interactions for seniors (1 in 10 users) and chronic pain sufferers (1 in 4 adults).
- Healthcare/Research: Enables more robust studies, informing prescribing practices; aligns federal policy with 40+ state medical marijuana programs.
- No Explicit International Relations Impact.
Main Stakeholders Affected
- Patients and Consumers: Chronic pain sufferers, seniors, veterans, chemotherapy patients, and CBD users (1 in 5 adults, 15% seniors).
- Healthcare Providers: ~30,000 practitioners recommending marijuana; need better efficacy/safety data.
- Researchers and Manufacturers: Scientists facing prior Schedule I barriers; hemp/CBD producers seeking clearer regulations.
- Government Entities: DOJ/DEA (rescheduling), HHS/FDA/NIH/CMS (research/regulation), Congress (legislative updates), states with medical programs.
- General Public: Those impacted by product safety/labeling issues in CBD market.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on President's authority under Constitution/CSA; rulemaking must follow Administrative Procedure Act (e.g., public comments, hearings); hemp changes require congressional action, not unilateral executive power. Standard disclaimers preserve agency authorities and avoid private rights of action.
- Constitutional: Invokes Article II executive authority; no apparent conflicts with federalism, as it defers to state programs and existing law.
- Political: Addresses public health gaps (e.g., 43,000 comments on proposed rule), veteran/senior needs, and state-federal tensions; promotes evidence-based policy without legalizing recreational use.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.